iTeos Therapeutics (NASDAQ:ITOS) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note published on Monday, Benzinga reports. They currently have a $46.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Wedbush reiterated an outperform rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, August 8th. Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an overweight rating and a $31.00 target price for the company. Finally, JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an overweight rating for the company in a research report on Monday, August 12th.

iTeos Therapeutics Price Performance

ITOS opened at $11.59 on Monday. The company has a fifty day moving average price of $16.12 and a 200-day moving average price of $14.63. The firm has a market capitalization of $418.67 million, a P/E ratio of -3.07 and a beta of 1.39. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.86. The firm had revenue of $35.00 million for the quarter, compared to analysts’ expectations of $4.20 million. On average, analysts expect that iTeos Therapeutics will post -4.21 earnings per share for the current year.

Institutional Trading of iTeos Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new stake in iTeos Therapeutics in the first quarter worth $3,337,000. Jump Financial LLC bought a new position in shares of iTeos Therapeutics during the fourth quarter valued at about $636,000. Candriam S.C.A. bought a new position in shares of iTeos Therapeutics during the second quarter valued at about $7,558,000. Kennedy Capital Management LLC bought a new position in shares of iTeos Therapeutics during the first quarter valued at about $1,988,000. Finally, Quest Partners LLC bought a new position in shares of iTeos Therapeutics during the fourth quarter valued at about $90,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.